Akademik Veri Yönetim Sistemi
Discover Oncology, cilt.17, sa.1, 2026 (SCI-Expanded, Scopus)
Background: Head and neck squamous cell carcinoma (HNSCC) has poor survival outcomes, particularly in locally advanced stages. Identifying prognostic factors can help personalize treatment and improve outcomes. Method: We retrospectively analyzed stage III-IVA/B HNSCC patients who received definitive or adjuvant CRT from January 2015 to January 2024. Demographic, clinical, and laboratory data were collected. Results: The study included 138 patients. A total of 84 patients received CRT for the definitive aim, while 55 patients received it for the adjuvant aim. The median event free survival (EFS) was 7.65 years (95%CI 6.14–9.15). Factors associated with poor EFS in multivariate analysis were stage IVA/B disease (HR 2.58, 95%CI 1.21–5.49), being underweight (HR 3.54, 95%CI 1.57–7.96), and higher NLR (HR 2.51, 95%CI 1.30–4.85). Stage IVA/B disease were associated with poorer OS in multivariate analysis (HR 3.07, 95%CI 1.22–7.69). Male gender was associated with prolonged EFS and overall survival (HR 0.51, 95%CI 0.27–0.96 and HR 0.33, 95%CI 0.15–0.74, respectively). Conclusion: In conclusion, female gender, stage IVA/B disease, being underweight, and having a high NLR were independent predictors of EFS while female gender and stage IVA/B disease were independent predictors for OS in patients with HNSCC who were treated with CRT.